Healthcare Regulation (HIPAA)

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

The strategic acquisition of veteran attorney Mark Tabakin and his six-person team signals a major escalation in Scarinci Hollenbeck's statewide ambitions.

EZContacts' new 'top retailer' award highlights the online eyewear boom. But the real story is the underlying system reshaping a regulated, high-friction industry.

As corporate interests reshape medicine, a leading physician's call for stewardship revives a debate on the soul of healthcare. Can timeless values survive?

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

A new report shows California's self-insured employers face a puzzling trend: workers' comp claims are at a 5-year low, yet costs are surging. Why?

With CE Mark approval for its SOUND REACH Swift, Genesis MedTech brings a 'plug-and-play' ultrasonic shear to Europe, promising to simplify complex open surgeries.

Provincial governments are using a constitutional override to end labour disputes, sparking a national outcry. Is this a savvy tactic or an erosion of rights?

Intended to heal, some Physician Health Programs are accused of using flawed science and financial coercion to ruin careers. Are they a safety net or a trap?

As Capital Edge marks 16 years by reaffirming its niche focus, we explore the explosive growth of specialized consulting driven by byzantine federal rules.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

A pivotal partnership between WeInfuse and Trial IQ leverages AI to bring clinical trials to local infusion centers, signaling a major shift in drug development.

Cell therapies promise miracles, but a decades-old test for cell health is flawed. A new global standard aims to bring much-needed precision and safety.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

A novel probiotic, sourced from an elite athlete's gut, has navigated the FDA's complex regulatory maze, signaling a major shift for the entire industry.

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

A new partnership is democratizing science for wellness brands, making it faster and cheaper to prove their final products work and earn customer trust.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

A surprising innovation is changing surgical recovery. New research shows preoperative Botox can halve opioid use for jaw surgery patients. A breakthrough?